ERBB2 and breast cancer: The pCR rate of neoadjuvant chemotherapy can reach 30–50% in patients with TNBC and HER2-positive breast cancer, while the pCR rate of neoadjuvant chemotherapy is only 5–15% in patients with luminal subtypes [8, 10].